Figures & data
Table 1 Formalin Study Design
Table 2 Arthritis (CFA Ankle): Study Design
Table 3 Neuropathic Pain (SNL): Study Design
Table 4 Bone Cancer Study Design
Figure 1 Formalin testing.
Notes: *CAV1001 10mg/kg v. vehicle (30-35 min), p<0.03; Phase 2 comparisons (cumulative: 20-35 min): CAV1001 10mg/kg v. vehicle, p<0.003; ICI204448 10mg/kg v. vehicle, p<0.05; CAV1001 10mg/kg v. ICI204448 10mg/kg, p<0.01.
Figure 2 Dose-response: CAV1001 versus ICI204448.
Figure 3 Efficacy of CAV1001 in CFA-induced JCT reduction.
Notes: +: p<0.02; ++: p<0.002; *: p<0.01; **: p<0.001; ***: p<0.0002 (one-way ANOVA).
Figure 4 Efficacy of CAV1001 in SNL-induced mechanical hyperalgesia.
Notes: +: p<0.05; *; p<0.05; ***: p<0.0003 (one-way ANOVA).
Figure 5 Effect of CAV1001 and morphine on pain induced weight bearing.
Notes: Morphine compared to BL: +++: p<0.001, ++: p <0.006, +: p = not significant; CAV1001 compared to BL: *: p<0.003 (one-way ANOVA).
